Animab has successfully closed a EUR 10 million Series B funding round to support the launch of its innovative antibiotic-free livestock health solution, Nanoprotec®, amid growing concerns over antimicrobial resistance.

Information on the Target

Animab, a pioneering biotechnology company based in Zwijnaarde, focuses on developing innovative oral antibody solutions to address unmet needs in the production animal sector. The company's flagship product, Nanoprotec®, is a first-in-class oral monoclonal antibody designed to target enterotoxigenic Escherichia coli (ETEC) F4, which is known to cause severe diarrhea in piglets. This condition leads to poor growth rates and a significant increase in mortality among young livestock, affecting more than 60 million piglets annually across the European Union.

The recent closing of a EUR 10 million Series B funding round positions Animab to commercialize Nanoprotec® and advance its broader pipeline of products. This capital infusion comes on the heels of a strategic distribution agreement with Huvepharma, furthering the company’s momentum towards market entry in Europe.

Industry Overview in the Target’s Specific Country

The animal health market in the European Union is undergoing significant transformation, driven by increasing concerns over antimicrobial resistance (AMR) and the demand for sustainable agriculture. As traditional antib